Search research articles
Contact Us
Filters
Showing results (51-60 of 111) with videos related to
Page
of 12
Sort By:
European Urology Oncology
|
April 30, 2025
Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial
Rohit K Jain, Umang Swami, Mehmet A Bilen, et al.
The Prostate
|
August 30, 2023
Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancer
Nishita Tripathi, Vinay Mathew Thomas, Nicolas Sayegh, et al.
Clinical Genitourinary Cancer
|
December 25, 2024
Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
Nicolas Sayegh, Yeonjung Jo, Georges Gebrael, et al.
Prostate Cancer and Prostatic Diseases
|
August 24, 2023
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors
Georges Gebrael, Nicolas Sayegh, Vinay Mathew Thomas, et al.
Prostate Cancer and Prostatic Diseases
|
July 17, 2023
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors
Georges Gebrael, Nicolas Sayegh, Vinay Mathew Thomas, et al.
Cancers
|
June 19, 2024
Treatment Patterns and Outcomes by Age in Metastatic Urinary Tract Cancer: A Retrospective Tertiary Cancer Center Analysis
Nishita Tripathi, Georges Gebrael, Beverly Chigarira, et al.
Cancers
|
October 13, 2021
Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States
Umang Swami, Jennifer Anne Sinnott, Benjamin Haaland, et al.
Cancer
|
January 5, 2024
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade
Eric J Miller, Tracy L Rose, Benjamin L Maughan, et al.
Cancer Chemotherapy and Pharmacology
|
November 10, 2016
Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer
Benjamin L Maughan, Daniel L Suzman, Brandon Luber, et al.
Therapeutic Advances in Urology
|
November 11, 2024
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix
Patrick Campbell, Georges Gebrael, Arshit Narang, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 111) with videos related to
Sort By:
Page
of 12
European Urology Oncology
|
April 30, 2025
Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial
Rohit K Jain, Umang Swami, Mehmet A Bilen, et al.
The Prostate
|
August 30, 2023
Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancer
Nishita Tripathi, Vinay Mathew Thomas, Nicolas Sayegh, et al.
Clinical Genitourinary Cancer
|
December 25, 2024
Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
Nicolas Sayegh, Yeonjung Jo, Georges Gebrael, et al.
Prostate Cancer and Prostatic Diseases
|
August 24, 2023
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors
Georges Gebrael, Nicolas Sayegh, Vinay Mathew Thomas, et al.
Prostate Cancer and Prostatic Diseases
|
July 17, 2023
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors
Georges Gebrael, Nicolas Sayegh, Vinay Mathew Thomas, et al.
Cancers
|
June 19, 2024
Treatment Patterns and Outcomes by Age in Metastatic Urinary Tract Cancer: A Retrospective Tertiary Cancer Center Analysis
Nishita Tripathi, Georges Gebrael, Beverly Chigarira, et al.
Cancers
|
October 13, 2021
Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States
Umang Swami, Jennifer Anne Sinnott, Benjamin Haaland, et al.
Cancer
|
January 5, 2024
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade
Eric J Miller, Tracy L Rose, Benjamin L Maughan, et al.
Cancer Chemotherapy and Pharmacology
|
November 10, 2016
Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer
Benjamin L Maughan, Daniel L Suzman, Brandon Luber, et al.
Therapeutic Advances in Urology
|
November 11, 2024
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix
Patrick Campbell, Georges Gebrael, Arshit Narang, et al.
Page
of 12